DBT-JRF (BET)

DBT-JRF (BET) is not a college-admission examination. It is an all-India qualifying examination for a DBT doctoral research fellowship in biotechnology and life sciences. A candidate who earns Category-I status still needs to secure admission and PhD registration at a recognized university or institution; DBT/RCB do not place candidates into PhD programmes.

paragraphs_placeholder

• The DBT-JRF programme was initiated in 2004 to develop skilled research human resources and support doctoral research in frontier biotechnology.
• The fellowship is tenable at a recognized university or institution in India where the selected candidate registers for a PhD.
• BET is ordinarily held once each year, but applicants should rely on the current official notification rather than assume a date or schedule.

Under the BET 2026 rules, eligible academic routes included: a four-year/eight-semester UG degree in biotechnology, life sciences or listed allied disciplines; a B.Tech/B.E.; or a relevant master's/equivalent degree such as M.Sc., M.Tech., M.V.Sc., M.Pharm., integrated M.Sc./M.Tech. or MBBS. Relevant allied areas expressly included biomedical science, bioinformatics, biochemistry, biophysics, botany, chemistry, computational biology, genetics, microbiology and zoology, among other biology/life-sciences areas.

Final-year and result-awaited candidates could apply in the result-awaited category, but had to submit the prescribed attestation/undertaking certified by the head of their institution. Eligibility is verified for shortlisted candidates, so meeting the application condition does not remove the need to supply valid documents later.

• For a four-year research bachelor's degree, the 2026 notice specified at least 75% aggregate marks or equivalent grade, with a 5% relaxation/equivalent grade as applicable under the referenced UGC PhD regulations.
• For B.Tech/B.E. and relevant master's/equivalent qualifications, the 2026 threshold was 60% for General, EWS and OBC candidates and 55% for SC/ST/differently abled candidates.
• The 2026 age limit was 28 years on the application closing date for General/EWS candidates, with up to five years' relaxation for SC/ST/differently abled/women candidates and up to three years for OBC-NCL candidates.
• The 2026 notice required the applicant to be a bona fide citizen and resident of India. Because eligibility rules can change, prospective applicants should use the notice for their own cycle.

BET 2026 used a 300-mark multiple-choice format. Section A had 50 compulsory questions worth three marks each, while Section B offered 150 biotechnology-specialism questions, of which a candidate had to attempt 50, also worth three marks each. Both sections applied negative marking: one mark was deducted for each incorrect answer, while unattempted questions received zero.

Section A covered general science, mathematics, chemistry, general aptitude, analytical and quantitative ability, and general biotechnology. Section B covered specific biotechnology areas according to the official syllabus. The official 2026 bulletin continued to point candidates to the DBT-JRF BET syllabus document hosted by RCB.

• Section A: 50 questions; all 50 compulsory; 150 marks.
• Section B: 150 questions offered; answer 50; 150 marks.
• Total: 200 questions offered, 100 answered, 300 marks.
• Medium: English; mode: computer-based test; duration: three hours.

BET applications are submitted online through the NTA GAT-B/BET portal. In the 2026 process, candidates registered with their own email address and mobile number, completed the form, uploaded the required scanned records, paid online, and retained the confirmation page. The bulletin lists photo, signature, identity proof, date-of-birth proof, category certificate where applicable, PwD certificate where applicable, and the result-awaited certificate where applicable among the uploads.

For date context, the published BET 2026 application window ran from 19 March 2026 to 9 April 2026 (5:00 PM), with fee payment allowed until 11:50 PM on 9 April and a correction period from 11 to 13 April 2026. Those dates have passed; they are useful only as the 2026 record, not as a prediction of a future cycle's deadline.

• Use one application only; the 2026 bulletin stated that multiple applications would not be accepted.
• Download and retain the confirmation page after successful payment.
• Check official RCB, NTA and DBT notices for the next application window, correction window, admit-card instructions and result updates.

Build preparation around the two-part design rather than treating BET as only a subject-recall test. Section A is compulsory and mixes 10+2-level general science, mathematics and chemistry with aptitude, analytical/quantitative ability and general biotechnology. Section B requires selective answering: candidates should develop sufficient breadth to identify their strongest 50 questions among the 150 specialised biotechnology questions offered.

Use timed computer-based practice and an error-review log. This is particularly important because every wrong answer carries a one-mark penalty against a three-mark correct answer; therefore, question selection and accuracy matter alongside coverage. Read the RCB-hosted syllabus named in the current bulletin before making a topic plan.

• First, map the official syllabus into Section A foundations and the Section B biotechnology areas in which you are strongest.
• Practise answering a 100-question, three-hour paper, including decisions about which 50 Section B questions to attempt.
• Revise quantitative/analytical methods as well as biology and biotechnology content; all are explicitly included in Section A.
• Use official notifications and the official syllabus as the authoritative reference if coaching materials conflict with them.

Category-I is the direct DBT-JRF outcome. It can be activated after the candidate joins and subsequently registers for a PhD at a recognized Indian university or institution, within two years of the award-letter date under the 2026 terms. Obtaining a BET Category-I result therefore does not by itself create a PhD seat: the candidate must independently meet the host institution's PhD admission and selection requirements.

Category-II is a distinct merit-list outcome. It can make a candidate eligible for appointment to a DBT-sponsored project with fellowship equivalent to NET/GATE qualification under current DST guidelines, and/or for PhD enrolment subject to institutional selection. However, the 2026 rules explicitly state that Category-II does not entitle the candidate to a DBT-JRF fellowship and does not oblige a principal investigator to hire from that list.

• Dated 2026 fellowship context: activated Category-I fellows were to receive ₹37,000 per month as JRF for two years, then ₹42,000 per month as SRF for the remaining three years after the required assessment; HRA where applicable and ₹30,000 annual contingency on a pro-rata basis were also stated. These amounts and terms can be revised, so applicants should confirm the current award notice.
• Document verification applies to shortlisted candidates; an award letter is not issued if eligibility is not established or required records are incorrect or missing.
• The programme's broader outcome is funded doctoral training and research in biotechnology/life sciences, rather than a standalone professional licence or guaranteed employment.